Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Denintuzumab mafodotin
Другие языки:

    Denintuzumab mafodotin

    Подписчиков: 0, рейтинг: 0
    Denintuzumab mafodotin
    Mafodotin ADCs.svg
    Monoclonal antibody
    Type Whole antibody
    Source Humanized (from mouse)
    Target CD19
    Clinical data
    Other names SGN-19A
    ATC code
    • none
    Identifiers
    CAS Number
    ChemSpider
    • none
    UNII
    KEGG

    Denintuzumab mafodotin (INN; development codes SGN-19A or SGN-CD19A) is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle Genetics.

    Denintuzumab refers to the anti-CD19 antibody, and mafodotin refers to MMAF and the chemical linkage.

    Clinical trials

    The drug is in phase I clinical trials. Preliminary phase I results for B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL) were presented at the ASH medical conference Dec 2015.

    Phase 2

    A separate randomized phase 2 trial started in 2015 to evaluate SGN-CD19A in combination with R-ICE chemotherapy for second-line DLBCL. A phase 2 clinical trial in front-line DLBCL is started in 2016. Both trials were terminated by the sponsor based on portfolio prioritization.



    Новое сообщение